Sangamo Therapeutics France
Sangamo Therapeutics France is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
Sponsor Sangamo Therapeutics France
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Recruitment was permanently stopped before full enrolment was achieved, resulting in a smaller-than-planned sample size.
- Early recruitment termination meant that the planned Bayesian Optimal Interval dose-escalation process did not meet its pre-specified stopping criteria.
- Limited available biopsy material constrained interpretation of chronic graft-related findings.
- Mixed lymphocyte reaction assay data were limited by low peripheral blood mononuclear cell availability after anti-thymocyte globulin lymphodepletion, precluding conclusions.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Sangamo Therapeutics France?
The 2026-10-09 snapshot links Sangamo Therapeutics France to 1 distinct CTIS trials. Recorded services include Project management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Sangamo Therapeutics France?
The most frequently recorded therapeutic areas are Nephrology, Transplantation. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Sangamo Therapeutics France conducted?
The linked trials record locations in 2 countries, including Belgium, Netherlands. These are trial locations, not confirmed office locations or countries where Sangamo Therapeutics France delivered services.
What can this page tell me about Sangamo Therapeutics France's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Sangamo Therapeutics France. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Sangamo Therapeutics France